Passage BIO, Inc. (PASG) stock
PASGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$4.25+0.24 (+5.99%)
Close on Nov 13, 2026Market cap $13.68MP/E –Yield –
Earnings
Passage BIO's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
–
Not yet scheduled
Revenue, Q4 FY2025
–
EPS, Q4 FY2025
$4.09
-$0.20 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Passage BIO's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2025ended Dec 31, 2025 | Mar 3, 2026before the open | – | – | $4.09 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 10, 2025after the close | – | – | -$2.44 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 12, 2025before the open | – | – | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 13, 2025before the open | – | – | -$0.25 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 4, 2025before the open | – | – | -$0.20 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 13, 2024before the open | – | – | -$0.31 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 8, 2024before the open | – | – | -$0.26 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 14, 2024before the open | – | – | – | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 4, 2024before the open | – | – | -$0.30 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 13, 2023before the open | – | – | -$0.49 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 7, 2023before the open | – | – | -$0.44 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 11, 2023before the open | – | – | -$0.63 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 6, 2023before the open | – | – | -$0.50 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 10, 2022before the open | – | – | -$0.49 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 4, 2022before the open | – | – | -$0.73 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 16, 2022before the open | – | – | -$0.79 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 3, 2022before the open | – | – | -$0.95 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 4, 2021before the open | – | – | -$0.87 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 5, 2021before the open | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 5, 2021before the open | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 3, 2021before the open | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 10, 2020before the open | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Aug 13, 2020before the open | – | – | – | Filing |
| Q1 FY2020ended Mar 31, 2020 | May 11, 2020before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Passage BIO has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Passage BIO puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Passage BIO filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- News
- News
- News
- Results
See a number that looks wrong?